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The role of accelerated hyperfractionated radiotherapy
in the treatment of inoperable non-small cell lung cancer:
a controlled clinical trial
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Jan Sko∏yszewski, Stanis∏aw Korzeniowski, Pawe∏ Dymek, Tomasz Walasek,
Marta Weiss, Krystyna Zawi∏a, Piotr Brandys
I n t r o d u c t i o n.  Radiotherapy remains the basic form of treatment in cases of non-small cell lung cancer (NSCLC) but the-
re still exist controversies concerning optimal radiotherapy regimen and in particular, the total dose and fractionation schedu-
les.
P u r p o s e.  To prove whether the question: if using an unconventional dose fractionation regimen (accelerated hyperfractio-
nation) could improve the results of palliative teleradiotherapy patients with NSCLC.
M a t e r i a l  a n d  m e t h o d s.  Between 1997 and 2000 in the Cancer Centre in Kraków (COOK) a controlled clinical trial was
conducted in a group of 150 patients with locally advanced (III°) inoperable and unsuitable for radical radiotherapy
NSCLC, with no major symptoms of the disease. In 76 patients conventionally fractionated radiotherapy was performed – 50
Gy in 25 fractions during 5 weeks (CF). 74 patients were irradiated twice a day (AHF); the dose per fraction was 1.25 Gy and
the minimum interval between fractions – 6 hours. The total dose was 50 Gy in 40 fractions during 26 days.
Re s u l t s. The probability of 12 months survival was 47.4% in the CF arm and 45.9% in the AHF arm; the probability of 24
months survival was 16.2% and 15.8% respectivly. In all 76 patients in CF arm the treatment was carried out in prescribed ti-
me without breaks. Out of 74 patients in the AHF group 8 (10,8%) did not complete the treatment and 2 of them died in 3 rd
and 4 th week of treatment.
C o n c l u s i o n.  The use of accelerated hyperfractionation does not improve the results of palliative teleradiotherapy in patients
with locally advanced NSCLC without severe symptoms related to intrathoracic tumor. The treatment of choice in this group
of patients is conventionally fractionated radiotherapy with a total dose of 50 Gy in 25 fractions in 5 weeks of treatment.
Ocena skutecznoÊci teleradioterapii metodà przyspieszonej hiperfrakcjonacji
w paliatywnym leczeniu chorych na nieoperacyjnego, niedrobnokomórkowego raka p∏uca:
kontrolowane doÊwiadczenie kliniczne
W s t ´ p.  Podstawowà metodà paliatywnego leczenia chorych na niedrobnokomórkowego raka p∏uca (NKRP) jest teleradio-
terapia; nadal jednak istniejà kontrowersje dotyczàce wyboru optymalnych warunków napromieniania, a w szczególnoÊci daw-
ki ca∏kowitej i sposobu jej frakcjonowania.
C e l  p r a c y.  Odpowiedê na pytanie: czy zastosowanie niekonwencjonalnego sposobu frakcjonowania dawki promieniowa-
nia (przyspieszona hiperfrakcjonacja) mo˝e poprawiç wyniki paliatywnej radioterapii chorych na NKRP.
M a t e r i a ∏.  W latach 1997–2000 w krakowskim oddziale Centrum Onkologii (COOK) przeprowadzono kontrolowane
doÊwiadczenie kliniczne w grupie 150 chorych na miejscowo zaawansowanego (III°) NKRP, nie kwalifikujàcych si´ do rady-
kalnego leczenia chirurgicznego lub napromienianiem, u których nie stwierdzono nasilonych objawów zwiàzanych z rozrostem
nowotworu w terenie klatki piersiowej. 76 chorych napromieniano paliatywnie dawkà 50 Gy w 25 frakcjach w czasie 5 tygo-
dni (KF), 74 chorych napromieniano paliatywnie metodà „2 x dziennie” dawkà frakcyjnà 1,25 Gy z przerwà mi´dzy frakcja-
mi 6 godzin, dawkà ca∏kowità 50 Gy w 40 frakcjach w ca∏kowitym czasie leczenia 26 dni (PHF).
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Introduction
Between 1992 and 1996 in the Cancer Centre in Kraków
a controlled clinical trial (KBN grant no 4 S402 111 06)
was conducted in a group of 216 patients with locally ad-
vanced, inoperable and unsuitable for radical radiothera-
py NSCLC, with no major symptoms of the disease [1,
2]. In the study group the irradiated patients have longer
overall survival and better quality of life in comparison
with the patients on supportive care only. Of the two
compared fractionation regimens (hypofractionation ver-
sus conventional fractionation), the conventional fractio-
nation (total dose 50 Gy, 2 Gy per fraction, 5 days per we-
ek, in 5weeks of treatment) appeared superior. Never-
theless the results were disappointing: one-year survival
did not exceed 32%, 2 years – 14%, mean survival was
11 months.
In this situation, from 1.01.1997 till 30.03.2000 in
COOK another controlled clinical trial was carried out, to
find out if using an unconventional dose fractionation
regimen (accelerated hyperfractionation) could improve
the results of palliative teleradiotherapy in this group of
patients.
The aim of this paper is the analysis of to analyse of
this 3 years study comprising 150 patients accrued to the
trial.
Material and methods
Before the trial began we obtained the approval of the Ethics
Committee at COOK. Every patient enrolled into the trial gave
signed informed consent.
1. The eligibility criteria were as follows:
(a) microscopically confirmed NSCLC, unsuitable for radical
surgery or teleradiotherapy,
(b) age less than 70 years,
(c) stage III of the disease according to TNM UICC 1997 sta-
ging system with exception of patients with metastases to
supraclavicular lymph nodes,
(d) performance status at least 50 according to Karnofsky scale,
(e) no prior anticancer treatment,
(f) no major symptoms of tumour spread in the chest which
are classic indications for palliative radiotherapy (e.g. su-
perior vena cava syndrome, marked effort dyspnoea due to
main bronchus or carina infiltration, fully developed Panco-
ast syndrome, and massive haemoptisis).
2. Every patient had following examinations and tests carried
out:
Bronchoscopy with biopsy of a sample for microscopic exami-
nation, chest X – ray (PA and lateral), brain CT (in patients
with adenocarcinoma), spirometry, gasometry, abdomen ul-
trasound, blood test with differential white cell count, blood
biochemistry (evaluating the function of parenchymal or-
gans – transaminases, GGTP, bilirubin, creatinin, BUN, glu-
cose, LDH, serum protein with electrophoresis).
The performance status was estimated according to Karno-
fsky scale.
3. The patients fulfilling the inclusion criteria were subsequen-
tly randomly assigned to one of the two groups:
(a) first group – „twice a day” regimen (AHF – accelerated
hyperfractionation)
beam parameters: megavoltage X rays, beam energy
10MV,
technique: 1 Stage (up to 40 Gy): two opposed AP -PA
portals encompassing the tumour with a 2 cm margin,
unilateral hilum and mediastinum and in patients with N3
– contralateral hilum.
2 Stage (up to 50 Gy) three intersecting beams encom-
passing the tumour volume.
dose: two fractions daily, fraction dose 1.25 Gy, inter-
fraction interval 6 hours; tumour dose: 50 Gy in 40 frac-
tions during 20 days of irradiation in total treatment time
of 26 days. (The treatment started on Monday and was
carried out 5 days per week).
(b) second group: conventional fractionation regimen (CF)
Beam characteristics and radiotherapy technique as in
the first group.
Dose: 50 Gy in 25 fractions during 5 weeks of treatment.
In both groups computer assisted treatment planning
based on CT scans was used, the doses were estimated in
ICRU reference points. All fields were treated daily.
Caution: the treatment was considered with palliative
intent and therefore we used low fraction dose (1.25 Gy)
in AHF arm and low total dose (50 Gy) in CF arm.
4. The assignment of a patient to one of the study groups was
performed using the random number table method described
by Peto et al. [3].
5. Follow up: all patients were controlled every two months
with tests listed in paragraph 2 of the protocol except bron-
choscopy. Thorax CT (if indicated) was repeated every 4-6
months.
6. The main endpoints were 12 and 24 months overall survival.
The analysis of the quality of life was based on performance
status estimation according to Karnofsky scale. To compare
the efficacy of the two radiotherapy regimens in local control,
the regression level of the tumour on X – ray films was evalu-
ated 8 weeks after treatment completion.
7. Statistical analysis: the survival probability was estimated
with Kaplan – Meier method [4] and in statistical differences
analysis log – rank test (according to Peto et al.) was used [5].
W y n i k i.  Prawdopodobieƒstwo prze˝ycia 12 miesi´cy wynios∏o 47,4% w grupie chorych napromienianych KF, a 45,9% w gru-
pie chorych napromienianych PHF; prawdopodobieƒstwo prze˝ycia 24 miesi´cy wynios∏o odpowiednio: 16,2% i 15,8%.
U wszystkich 76 chorych napromienianych KF leczenie przeprowadzono w planowanym czasie bez przerw. SpoÊród 74 cho-
rych napromienianych PHF, u 8 tzn. 10,8% nie dokoƒczono napromieniania: 2 z tych chorych zmar∏o w 3 i 4-tym tygodniu
leczenia.
W n i o s k i.  Zastosowanie przyspieszonej hiperfrakcjonacji dawki nie poprawia wyników paliatywnej teleradioterapii chorych
na miejscowo zaawansowanego NKRP, u których nie stwierdza si´ ci´˝kich objawów zwiàzanych z szerzeniem si´ nowotwo-
ru w terenie klatki piersiowej. Post´powaniem z wyboru w tej grupie chorych pozostaje napromienianie z zastosowaniem kla-
sycznej frakcjonacji z podaniem dawki 50 Gy w 25 frakcjach w czasie 5 tygodni.
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The survival was calculated from the date of randomisation to
the date of a patient's death or his last visit in the COOK. The
shortest follow – up was 6 months.
The survival was calculated in all patients.
From January 1997 to March 2000 150 patients with lo-
cally advanced, inoperable, unsuitable for radical radiotherapy
NSCLC, without major chest symptoms were entered into the
trial. According to the randomisation: in 74 patients accelerated
hyperfractionation (”twice a day”) radiotherapy was carried out
and 76 patients were conventionally irradiated. The population
and clinical data of both compared patients groups are presented
in Table I.
Table I shows that the analysed groups of patients did not
differ in respect of population and clinical characteristics.
n all 76 patients in the CF arm the treatment was carried
out in prescribed time, without breaks. At the end of radio-
therapy and after completing the treatment in all these pa-
tients dysphagia was observed as a sequel of oesophagus irra-
diation; the severity of the reaction did not exceed EORTC
grade 2 [6].
The tolerance of the treatment in the AHF group was mar-
kedly worse. Out of 74 patients 66 completed the treatment
(89.2%); in 6 patients oesophagitis was of grade 3 according to
EORTC classification. These patients required intensive anti-in-
flammatory treatment and 5-8 days breaks in radiotherapy. Out of
8 patients who did not complete the treatment 2 died in the 3rd
and the 4th week of treatment (one of them because of pulmona-
ry haemorrhage, the second one because of pneumonia with circu-
latory insufficiency); 6 patients went only trough the first part of
treatment (40Gy) because of infection and lung inflammatory
symptoms (4 patients) or circulatory insufficiency (2 patients).
In 1 patient in the CF and in 2 patients in the AHF group
in 3rd and 4th month after radiotherapy broncho -oesophageal
fistulas were diagnosed. These patients have died of uncontrol-
led local disease.
The evaluation of late complications is difficult because
in majority of patients only a short term palliative effect was
achieved.
The tolerance of the radiotherapy was worse and early
complications more frequent in the AHF group.
The results
The probability of 24 months survival in the groups is
presented in Fig.1.
The probability of 12 months survival was 47.4%
in the CF arm and 45.9% in the AHF arm; the probabi-
lity of 24 months survival was 16.2% and 15.8%, respecti-
vely.
The differences are not statistically significant (log
rank test, p>0.05). The mean survival was 10.8 and 10.6
months, respectively.
Table II presents the comparison of local control
with two methods of palliative radiotherapy in patients
with locally advanced, inoperable NSCLC.
Local control in the two compared fractionation re-
gimens was very similar, the observed differences are sta-
tistically insignificant (log rank test, p(0.05).
In both groups the most frequent cause of death we-
re distant metastases (almost 70%), accompanied by loco-
regional failure (the patients were treated with palliative
intent!).
Tab. I. The population and clinical data of both compared patients
groups
Population and clinical AHF CF
characteristics 74 patients 76 patients
No % No %
Sex:
M 65 87.8 66 88.2
F 9 12.2 9 11.8
Age:
Mean 59.2 years 59.1 years
<50 10 13.6 10 13.2
50 – 60 32 43.2 34 44.7
>60 32 43.2 32 42.1
Histopathology:
Squamous
cell carcinoma 67 90.5 68 89.5
Adenocarcinoma 6 8.1 7 9.2
Large cell carcinoma 1 1.4 1 1.3
Clinical stage (UICC 1997):
IIIA 26 35.1 26 34.2
IIIB 48 64.9 50 65.8
PS:
Mean 71 70
50 – 60 21 28.8 22 28.9
70 – 80 53 71.6 54 71.1
Fig. 1. The probability of 24 months survival in the groups
Tab. II. The level of radiological regression of the tumour
in two groups of patients irradiated with two different regimens
of dose fractionation
X – ray regression AHF CF
of the tumour No % No %
CR 5 6.6 5 6.8
> 50% 28 36.8 28 37.8
< 50% or progression 43 56.5 41 55.4
Total 76 100.0 74 100.0
366
Unfortunately, in the investigated group it was not
possible to carry out detailed quality of life assessment
(ECOG scale, QLQ – C30 questionnaire). Many patients
came for follow up visits irregularly, many of them refused
to fill the questionnaires. It was not possible to treat as in-
-patient in COOK all the patients with progressive dise-
ase, so they were admitted to pulmonological wards all
over south -eastern part of Poland.
The comparison of the quality of life in both gro-
ups of patients based on Karnofsky performance status es-
timated during follow up visits did not show statistically si-
gnificant differences between CF and AHF fractionation
regimens.
Discussion
Nearly 70% of patients with NSCLC are not quali-
fied for radical surgery or radical radiotherapy (65-75
Gy) because of advanced stage of the disease, poor per-
formance status and respiratory or circulatory insuffi-
ciency [7-9]. All these patients are potential candidates for
the most effective form of palliation which is teleradiothe-
rapy (despite the continuing progress in chemotherapy)
[1, 2, 10-15]. Regarding the usefulness of palliative ra-
diotherapy these patients could be divided into three gro-
ups:
(a) patients with clinically evident metastatic disease
or life threatening symptoms (brain metastases, weight
bearing bones involvement, spinal cord compression and
so on),
(b) patients with severe complaints caused by tu-
mour progression in the chest, that is with superior vena
cava syndrome, Pancoast syndrome, main bronchus or
tracheal progressive obstruction – irrespective of presen-
ce or absence of distant metastases,
(c) patients with locally advanced cancer without
distant metastases (III() and without major symptoms of
the tumour.
The patients from the first two groups have indispu-
table indications for palliative radiotherapy and most au-
thors in such cases prefer in this situation (especially in
group „a”) hypofractionation -short regimens using high
fraction doses (30 Gy/10fr., 20 Gy/5fr., 10 Gy/1fr.) [9-11,
13, 14, 16].
The third group (patients with stage III lung can-
cer, unsuitable for radical surgery, or radical radiothera-
py, without marked symptoms of the disease). These pa-
tients cover some 20-30% of all NSCLC patients. As we
already mentioned in the introduction both our studies
and literature data show unequivocally that this group of
patients benefit from palliative radiotherapy [1, 2, 7, 9, 12-
-15] but still exist controversies concerning optimal ra-
diotherapy regimen and in particular the total dose and
fractionation schedules.
Literature data indicate that local tumour regres-
sion in patients with NSCLC has positive influence on
survival and there exists correlation between the total
dose and the level of tumour regression [13, 14, 15]. In ra-
dical radiotherapy of inoperable, locally advanced NSCLC
high doses (65-75Gy conventionally fractionated) are de-
livered. In palliative treatment such high doses and pro-
longed treatment are not only pointless but even contra-
indicated.
When designing described study we accepted 50 Gy
in 25 fractions in 5 weeks of treatment as the reference
protocol because it was well tolerated in our previous
study, which is one of important conditions of palliative
treatment [1, 2]. To maintain this good tolerance of radio-
therapy and at the same time to improve its efficacy we
decided to investigate hyperfractionated accelerated ra-
diotherapy regimen using „twice a day” irradiation and
keeping the total dose of 50 Gy. Theoretical basis and
potential benefits of accelerated hyperfractionation in
the treatment of cancers of different localisation are wide-
ly reported in literature [13]; in patients with NSCLC ac-
celerated hyperfractionation has been studied in numero-
us controlled and uncontrolled clinical trials [7, 13-15].
Most of these trials, however, deal with radical radiothe-
rapy and high total doses. The papers assessing the role of
accelerated hyperfractionation in palliative treatment are
rather scarce [15, 17, 18].
The analysis of the results of the trial in patients
with locally advanced NSCLC revealed that the efficacy of
the conventional fractionation (50 Gy in 25 fractions in 5
weeks treatment time) was very similar to that of accele-
rated regimen (50 Gy in 40 fractions, twice a day 1.25 Gy
for four weeks). The probability of 12 months survival
was 47.4% in the CF group and 45% in the AHF group;
mean survival was 10.8 and 10.6 months, respectively.
Tolerance of the treatment was better and early com-
plications were less frequent in the CF arm. Therefore the
use of AHF according to the protocol investigated in our
trial as palliative treatment in patients with locally ad-
vanced NSCLC is not justified and CF with total dose 50
Gy in 25 fractions in 5 weeks remains here the treatment
of choice.
Conclusion
1. The use of accelerated hyperfractionation does not
improve the results of palliative teleradiotherapy in
patients with locally advanced NSCLC without severe
symptoms related to intrathoratic tumor.
2. The treatment of choice in this group of patients is
conventionally fractionated radiotherapy with a total
dose of 50Gy in 25 fractions in 5 weeks of treatment.
Marian Reinfuss M.D. Ph.D.
Department of Radiation Oncology
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